Evenity (romosozumab-aqqg) is a monoclonal antibody indicated for the treatment of osteoporosis in postmenopausal women who are at high risk for fracture, including those with a history of osteoporotic fractures, multiple fracture risk factors, or those who have failed or are intolerant to other osteoporosis therapies.

Unlike many osteoporosis medications that only slow bone loss, Evenity has a dual mechanism of action. It blocks the activity of sclerostin, a protein that inhibits bone formation. This helps stimulate new bone growth while simultaneously reducing bone resorption, leading to increased bone mineral density and a lower risk of fractures.

Evenity is given as two subcutaneous injections once monthly by a healthcare provider for 12 consecutive months. After completing treatment with Evenity, patients are typically transitioned to another osteoporosis medication to help maintain the bone density gains achieved during therapy.

Benefits

• Builds new bone while reducing bone loss.
• Increases bone mineral density.
• Helps reduce the risk of vertebral, non-vertebral, and hip fractures.
• Monthly dosing administered by a healthcare professional.
• Recommended for women at very high risk of osteoporotic fractures.

Important Safety Information

Evenity may increase the risk of heart attack, stroke, and cardiovascular death in some patients and should not be used in individuals who have had a heart attack or stroke within the previous year. Patients should discuss their cardiovascular history with their healthcare provider before starting treatment.

Common side effects may include:

• Joint pain
• Headache
• Injection site reactions
• Muscle pain

Rare but serious side effects include:

• Osteonecrosis of the jaw
• Atypical femur fractures
• Low blood calcium levels
• Serious allergic reactions

Patients should ensure adequate calcium and vitamin D intake during treatment unless otherwise directed by their healthcare provider.

Active Ingredient: Romosozumab-aqqg
Drug Class: Sclerostin inhibitor (Monoclonal antibody)
Dosage Form: Solution for subcutaneous injection
Administration: Two subcutaneous injections once monthly for 12 months, administered by a healthcare professional.